Nick Leschly, 2seventy bio CEO (Jeff Rumans)
March 16, 2022 09:50 AM EDT
Financing
Bioregnum

With its share price chewed to pieces, Nick Leschly's 2sev­en­ty scores $170M to help weath­er the storm

John Carroll

Editor & Founder

A lit­tle more than a week af­ter blue­bird’s CFO an­nounced a quick ex­it as the com­pa­ny flagged an alarm about its abil­i­ty to sur­vive, the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times